微生物組市場規模、佔有率和成長分析（按產品、應用和地區）- 產業預測 2025-2032

2023 年全球微生物組市場規模價值9.11 億美元，預測期內（2025-2032 年）的複合年成長率為17.7%，從2024 年的10.7225 億美元成長至2032 年的39.4918 億美元。將成長至1000萬美元。

由於創新產品的湧入以及旨在研究和開發微生物組療法的策略夥伴關係關係的增加，微生物組市場正在經歷顯著成長。美國國立衛生研究院人類微生物組計劃等舉措正在增進我們對微生物組如何影響健康和疾病的理解。值得注意的合作，例如Hudson研究所於 2022 年 1 月與 BiomeBank 達成的四年協議，凸顯了我們對發現微生物治療方法的持續承諾。此外，與微生物組相關的疾病發病率的上升進一步推動了對標靶治療的需求。隨著興趣和研究的擴大，微生物組領域的新應用和治療選擇的潛力不斷成長，為這個不斷發展的市場的相關人員提供了充滿希望的機會。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究

微生物組市場規模（依產品）

• 市場概況
• 益生菌
• 食物
• 益生元
• 醫療食品
• 其他

微生物組市場規模（依應用）

• 市場概況
• 治療
• 診斷

微生物組市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Seres Therapeutics（USA）
• Ferring Pharmaceuticals（Switzerland）
• BiomeBank（Australia）
• Seed Health（USA）
• International Flavors & Fragrances Inc.（USA）
• Pendulum Therapeutics（USA）
• BioHM Health Inc.（USA）
• Actial Farmaceutica SRL（Italy）
• Optibiotix Health plc（UK）
• Resbiotic（USA）
• Infinant Health Inc.（USA）
• Biogaia AB（Sweden）
• Exegi Pharma LLC（USA）
• Vedanta Biosciences Inc.（USA）
• Enterome（France）
• Yakult（Japan）
• DuPont（USA）
• Metabiomics Corporation（USA）
• ViThera Pharmaceuticals（USA）
• Second Genome（USA）

結論和建議

Global Microbiome Market size was valued at USD 911.0 million in 2023 and is poised to grow from USD 1072.25 million in 2024 to USD 3949.18 million by 2032, growing at a CAGR of 17.7% during the forecast period (2025-2032).

The microbiome market is experiencing significant growth due to rising strategic partnerships aimed at research and development of microbiome therapies, alongside an influx of innovative product introductions. Initiatives like the Human Microbiome Project by the NIH are enhancing our understanding of how microbial flora impacts health and disease. Notable collaborations, such as the four-year agreement between Hudson Institute and BiomeBank in January 2022, highlight the ongoing commitment to discovering microbial treatments. Additionally, the escalating incidence of diseases linked to the microbiome is further fueling the demand for targeted therapies. As interest and research expand, the potential for new applications and treatment options in the microbiome space continues to increase, presenting promising opportunities for stakeholders in this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Microbiome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Microbiome Market Segmental Analysis

Global Microbiome Market is segmented by Product, Application and region. Based on Product, the market is segmented into Probiotics, Foods, Prebiotics, Medical food and Others. Based on Application, the market is segmented into Therapeutics and Diagnostics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Microbiome Market

The Global Microbiome market is driven by a heightened emphasis on the development of therapeutics targeting the human microbiome, particularly within the gut. Research has shown the vital role that gut microbiomes play in enhancing the effectiveness of medicinal drugs, with an optimal balance of microorganisms aiding in the treatment of various diseases. This relationship between specific bacteria and disease states paves the way for innovative medication and vaccine development. Significant investments in microbiome research, such as the National Institutes of Health's $215 million for the Human Microbiome Project and substantial EU funding initiatives like MetaHIT and Horizon 2020, underline this growing interest and increase in popularity for microbiome-based treatments.

Restraints in the Global Microbiome Market

The global microbiome market faces significant restraints primarily due to stringent government regulations. Notably, probiotics have yet to be recognized by the FDA as approved live biotherapeutic products, despite the availability of FDA-regulated foods and dietary supplements that contain these live organisms. These products cannot be marketed as effective treatments for diseases, which limits their potential in the marketplace. While some probiotics are currently undergoing clinical trials for potential future approval as biologics, the uncertainty surrounding FDA regulations poses a challenge for investment and research. Stricter regulatory measures could require extensive R&D efforts, discouraging significant investment and potentially stalling market growth.

Market Trends of the Global Microbiome Market

The Global Microbiome market is witnessing a notable trend of increasing collaborations between public and private organizations, driven by the proliferation of small innovative players. This dynamic landscape presents significant growth opportunities for key stakeholders seeking to acquire companies focused on microbiome research to discover new drugs and targets for various health conditions, including obesity, liver disorders, diabetes, and metabolic issues. As major market leaders prioritize strategic alliances and partnerships, the last two years have seen a surge in collaborative efforts to enhance product development pipelines through robust R&D initiatives, indicating a vibrant and evolving market poised for expansion.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Microbiome Market Size by Product & CAGR (2025-2032)

• Market Overview
• Probiotics
• Foods
• Prebiotics
• Medical food
• Others

Global Microbiome Market Size by Application & CAGR (2025-2032)

• Market Overview
• Therapeutics
• Diagnostics

Global Microbiome Market Size & CAGR (2025-2032)

• North America (Product, Application)
  • US
  • Canada
• Europe (Product, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Seres Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BiomeBank (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seed Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• International Flavors & Fragrances Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pendulum Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioHM Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actial Farmaceutica SRL (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Optibiotix Health plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Resbiotic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Infinant Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogaia AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exegi Pharma LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vedanta Biosciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enterome (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yakult (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DuPont (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabiomics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViThera Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Second Genome (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations